In the third episode of Season 3, we spoke with Dr. James Min, Founder and CEO of Cleerly Health, about his experience turning his clinical research into Cleerly and how he’s managed the business as the treatment of coronary artery disease evolves thanks to new research, new technology like generative AI, or new business models like value-based care reimbursement. Our discuss touches on processes to utilize to ensure product market fit, how firms should think about building healthcare AI products, and the importance of challenging dogma.

In the second episode of Season 3, we spoke with Dr. Barthalomew Sillah, COO of Avesta76 therapeutics about his experiences turning innovative science into impactful therapeutics. Our conversation touched on being open-minded to new opportunities, learning from non-biotech experiences in the healthcare ecosystem, and championing inclusion in the industry.

In the first episode of Season 3 of LifeSci Beat, we chatted with Eshwar Inapuri, Former CEO & Co-Founder of InnaMed. Our conversation spanned diagnostics company creation, navigating challenges as a young entrepreneur, and new frontiers and trends in the diagnostics space.InnaMed is an at-home blood testing company focused on improving the monitoring and treatment of patients undergoing heart failure, kidney transplant, hypoparathyroidism and in vitro fertilization. InnaMed was acquired by Fluxergy in 2023.

In this episode, we chatted with Dr. James Mutamba, CBO of Arrakis Therapeutics. Our conversation covered biotech IPO financing, the process of business development dealmaking, company creation, and the Arrakis Therapeutics platform. Arrakis Therapeutics is an preclinical private biotech developing RNA-targeted small molecules. They combine insights into RNA structure, chemistry, and biology to pioneer a new class of medicines focused on oncology and genetically validated diseases.

In this ninth episode, we spoke with Oriana Papin-Zoghbi, co-founder and CEO of AOA Dx. We discussed her global upbringing and early career, the current standard of ovarian cancer diagnosis, and building a company from academic research.

In the eighth episode of this season, we chatted with Alex Sapir about his various experiences leading life sciences companies through commercial launches and key funding milestones. We spoke about his career beginnings at GSK, ZS Associates, and United Therapeutics. Additionally, we covered his CEO tenures at Dova Pharmaceuticals and ReViral Ltd - both of which were acquired.

In this episode, we sat down with Geoff Meyerson — CEO & Co-Founder at Locust Walk. We discuss Geoff’s extensive life science career, which includes stints in investment banking, venture capital, and business development. We also dive into the founding story and journey of Locust Walk, a global investment bank that integrates corporate development strategy and execution with ​capital raising for innovative life science companies, and hear Geoff’s outlook on the year ahead for biotech.

In the sixth episode of our second season, we sat down with Dr. Pitamber "Pitou" Devgon, co-founder of Velano Vascular, active angel investor, and Lecturer at the Wharton School of Business. We discussed the origins of Velano Vascular’s central PIVO™ technology, the importance of collecting insightful data to de-risk early ventures, innovation through acquisition, and much more. Founded in 2012, Velano Vascular set out to transform the patient experience with PIVO™, a needle-free blood collection device. After inventing this breakthrough technology, Pitou led Velano Vascular's growth through eventual acquisition by BD in 2021.

In this episode, we chatted with Dr. Imogen Pryce, COO of R&D at Relay Therapeutics. Our conversation covered Relay Therapeutics’ scientific strategy, its unique Dynamo™ platform, and its underlying commercialization strategy and scientific differentiation. Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company that integrates disparate technologies to push drug discovery. Specifically, its Dynamo™ platform integrates leading-edge computational and experimental approaches designed to drug previously-intractable protein targets.

In the fourth episode of our second season, we spoke with Rami Elghandour, Chairman & CEO of Arcellx. Our conversation focused on the importance of building a company's culture from day one and how firms can turn their cultures into a competitive advantage. Arcellx is a clinical stage biotech company reimagining cell therapy. The company recently announced a strategic collaboration with Kite.